United Therapeutics (NASDAQ: UTHR) reported Q3 EPS of $3.50, $0.16 better than the analyst estimate of $3.34. Revenue for the quarter came in at $408.2 million versus the consensus estimate of $402.35 million.

For earnings history and earnings-related data on United Therapeutics (UTHR) click here.